Last reviewed · How we verify
Eye Therapies, LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Brimonidine Tartrate 0.025% | Brimonidine Tartrate 0.025% | phase 3 | Alpha-2 adrenergic agonist | Alpha-2 adrenergic receptor | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- China International Neuroscience Institution · 1 shared drug class
- Derm Research, PLLC · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Guangzhou Women and Children's Medical Center · 1 shared drug class
- Icahn School of Medicine at Mount Sinai · 1 shared drug class
- Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 shared drug class
- Al-Azhar University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Eye Therapies, LLC:
- Eye Therapies, LLC pipeline updates — RSS
- Eye Therapies, LLC pipeline updates — Atom
- Eye Therapies, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Eye Therapies, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eye-therapies-llc. Accessed 2026-05-16.